-
The markets are not out of the woods, but a number of potential plays have nearly reached attractive levels, including two well-supported ETFs, writes MoneyShow senior editor Tom Aspray .
FORBES: The Week Ahead: Should You Be Buying or Selling?
-
Eli Lilly , meanwhile, is touting data from its two amyloid drugs, including a pill drug that dramatically lowers levels of amyloid in the cerebral spinal fluid.
FORBES: Alzheimer's Drug Showdown
-
Eli Lilly (nyse: LLY - news - people ), meanwhile, is touting data from its two amyloid drugs, including a pill drug that dramatically lowers levels of amyloid in the cerebral spinal fluid.
FORBES: Alzheimer's Drug Showdown